Real-world evaluation of the effectiveness and safety of tirzepatide in patients with obesity: A prospective study.

BACKGROUND AND AIMS: Recent randomised controlled trials have demonstrated the efficacy of tirzepatide in inducing weight loss among adults with overweight or obesity, irrespective of diabetes mellitus status. However, evidence from real-world settings remains limited. This study aimed to evaluate the effectiveness and safety of tirzepatide for weight management in routine clinical practice.

METHODS

This prospective, longitudinal, observational study assessed the effects of tirzepatide in 107 participants with a body mass index of ≥30 kg/m2 or ≥27 kg/m2 and at least one weight-related comorbidity in real-world conditions. The primary outcomes were changes in body weight and body composition after 6 months of treatment. Secondary assessments included anthropometric and cardiometabolic parameters, quality of life, and tolerability.

RESULTS

The median tirzepatide dose at 6 months was 7.5 mg. At this visit, the mean body weight reduction was 18.04 kg, representing a 17.21% decrease from baseline. A total of 95.35% of participants achieved at least 5% weight loss, and 60.47% achieved ≥15%. Significant improvements were observed in glycaemic and lipid profiles, with enhancements in health-related quality of life and a favourable tolerability profile. The dropout rate was 3.7%.

CONCLUSIONS

This prospective real-world study confirms the effectiveness and safety of tirzepatide for weight management, even at maintenance doses lower than the approved dose, and supports findings from randomised clinical trials.